These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28132755)

  • 1. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
    Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
    J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
    Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
    Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
    de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
    Verburg FA; Hänscheid H; Biko J; Hategan MC; Lassmann M; Kreissl MC; Reiners C; Luster M
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):896-903. PubMed ID: 20033685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    Taprogge J; Abreu C; Yusuf S; Ainsworth G; Phillip RH; Gear JI; Gregory R; Leek F; Murray I; Coulson AB; Brown SR; Du Y; Newbold K; Wadsley J; Flux GD
    J Nucl Med; 2023 Jul; 64(7):1125-1130. PubMed ID: 37116914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
    Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
    Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
    Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
    N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.
    Plyku D; Hobbs RF; Wu D; Garcia C; Sgouros G; Van Nostrand D
    Ann Nucl Med; 2022 Mar; 36(3):213-223. PubMed ID: 35119623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
    Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I.
    Jentzen W; Bockisch A; Ruhlmann M
    J Nucl Med; 2015 Jun; 56(6):832-8. PubMed ID: 25858042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
    Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
    Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.